Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2024Current OncologyOpen Access

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDaniel KarelGeorge Washington UniversityCVClaire ValburgGeorge Washington UniversityNWNavitha WoddorGeorge Washington University Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Karel et al. (2024) studied this question.

synapsesocial.com/papers/68e708c0b6db643587682136https://doi.org/10.3390/curroncol31040148
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Distinct clinical and biological implications of CUX1 in myeloid neoplasms2019 · 45 citations
  2. 2Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study2023 · 184 citations
  3. 3The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort2018 · 138 citations
  4. 4Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy2017 · 56 citations
  5. 5Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis2013 · 285 citations